Happy Authors

Recently Published Articles
  • 2019, December

    case report

    A Rare Case of Gemcitabine-Induced Pulmonary HypertensionOpen Access

    PDF405.55 KB 405.55 KB
    Full-Text (HTML)
    Abstract [+]


    Gemcitabine is the backbone of systemic treatment of locally advanced and metastatic intrahepatic cholangiocarcinoma. In recent literature, gemcitabine has been linked to various pulmonary side effects.

    Case Report

    We report a case of an 82-year-old male who developed acute pulmonary hypertension after receiving one cycle of gemcitabine for metastatic cholangiocarcinoma. His symptoms began with fatigue associated with shortness of breath and cough that worsened despite dose reduction. He developed new onset bilateral pulmonary effusions and an echocardiogram revealed findings consistent with pulmonary hypertension. A computed tomography (CT) angiogram was negative for pulmonary thromboembolism. Although he was promptly treated with diuretics and steroids, the patient could not tolerate any further therapy.


    Gemcitabine-induced pulmonary hypertension is rare and can be challenging to diagnose, as it remains a diagnosis of exclusion. However, physicians should be vigilant of new pulmonary symptoms, as delayed treatment can cause significant patient morbidity and mortality.


    Cholangiocarcinoma; Gemcitabine; Pulmonary hypertension.


    CT: Computed Tomography; PE: Pulmonary Thromboembolism; GIPT: Gemcitabine-Induced Pulmonary Toxicity.

About the Journal

Pulmonary system plays a crucial role in human health. This system includes lungs and breathing muscles such as the diaphragm, wherein the respiratory system which is a part of the pulmonary system is involved in a mechanism known as Respiration. The respiration process enables the intake of oxygen and the liberation of carbon-dioxide between the organism and the environment.

Being the most important system which helps all the living organisms to sustain, it also acts as a medium to develop several risk factors leading to different disease or sometimes fatigue. The major risk factors include tobacco use, second-hand smoke, radon, occupational exposure, family history, chemical/gas disasters, allergens, air pollution, HIV/AIDS, airway anatomy, hypertension, birth effects, diet, obesity, and nutrition.

However, Openventio aims at the widespread propagation of all matters related to pulmonary and respiratory system through its Open Journal to all the scientific community for its welfare and control.

Aims and Scope

PRRMOJ covers a wide array of subjects as given below

  • Lung cancer molecular profiling
  • Chronic obstructive pulmonary disease (COPD)
  • Pediatrics and neonatal pulmonology
  • Geriatric pulmonology
  • Acute lung injury
  • Interstitial lung disease (ILD)
  • Bronchiological studies and diagnosis
  • Mechanical ventilation research
  • Lung transplantation
  • Pulmonary rehabilitation
  • Lung fibrosis and pneumonia
  • Pathological studies
  • Pulmonary hypertension and asthma
  • Lung cancer
  • Cellular respiration
  • Pulmonary thromboembolism

Submissions for this Journal are accepted from the very basic pulmonary research to the novel advancements.

The audience of PRRMOJ includes pulmonologists, chest medicine specialists, respiratory medicine specialists, respirologists, thoracic medicine specialists, pharmacologists, clinicians, researchers, physicians, surgeons, practitioners, educators, nurse, and students.

The journal welcomes all types of articles such as original research, review, case-report, mini-review, editorial, short-communication, book-review, opinion, commentary, Letter to the Editor, conference proceedings, technical report, errata, illustrations, etc.

We are open to receive comments and corrections from experts to improve the quality of our journal.